MH Survival without Dantrolene
malignant hyperthermia, intraoperative complications, postoperative complications, dantrolene, patient safety
Anesthesiology | Critical Care | Pathological Conditions, Signs and Symptoms | Patient Safety
Treatment of intraoperative malignant hyperthermia (MH) usually involves administration of IV dantrolene, which reduces the mortality from over 80% if untreated to less than 10%.1 When dantrolene is simply not available, physical and metabolic treatments must be employed. Patient survival is possible, as illustrated in three cases from one hospital in China.
Publisher or Conference
Anesthesia Patient Safety Foundation Newsletter
Simmons W, Feng D, Ma Z, Gu X, Huang J. MH Survival without Dantrolene. APSF Newsletter. 2020 August. Online Only. https://www.apsf.org/article/mh-survival-without-dantrolene/